Janus kinase inhibitors for inflammatory bowel disease

NICE recently recommended the janus kinase (JAK) inhibitor tofacitinib (Xeljanz) for second-line treatment of moderately to severely active ulcerative colitis. This article summarises the efficacy for tofacitinib in inflammatory bowel disease (ulcerative colitis and Crohn’s disease), and discusses a new JAK inhibitor, filgotinib, that has shown promise in Crohn’s disease.

Read the full article.

Add yours ↓
Web design and marketing agency Leamington Spa